J&J's Remicade Adds Psoriatic Arthritis Indication

FDA approves the supplemental indication for infliximab; J&J plans to differentiate Remicade from Amgen/Wyeth's Enbrel by highlighting Psoriasis Area Severity Index score improvements and reduction of symptoms of dactylitis and enthesopathy.